Clinical Trial

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy. The trial will test the hypothesis that clopidogrel is beneficial in preventing major adverse cardiovascular and cerebrovascular events (MACCE) in patients with subclinical coronary atherosclerosis identified on imaging.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-25; most recent amendment 2025-12-28.
Trial Details
NCT Number NCT05845489
Lead Sponsor Seoul National University Hospital
Collaborators: Samjin Pharmaceutical Co., Ltd., CKD Pharmaceutical Limited, Hanmi Pharmaceutical co., ltd., Yuhan Pharmaceutical Company, Daewoong Pharmaceutical Co. LTD., Dong-A ST Co., Ltd., IlDong Pharmaceutical Co Ltd
Conditions Coronary Artery Disease
Enrollment 11,086 participants
Start Date 2023-03-22
Primary Completion 2028-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-31